Study Reinforces Vaping Safer than Smoking Tobacco. Data shows Vaping does NOT cause cancer

With many smokers relying on vaping to satisfy their nicotine cravings, many worry about their health risks. Although e-cigarettes do not produce smoke, their nicotine content has left some vapers worried as to whether their vapor may damage DNA and lead to tumors. Those vapers can breath a sigh of relief as a new study has revealed e-cigarettes do NOT cause cancer. The finding re-enforces claims that e-cigs are a safer alternative to tobacco, the study claims.



According to Action on Smoking and Health, around 2.8 million adults in the UK use e-cigarettes. Researchers from London-based British American Tobacco exposed laboratory cells to the emissions of an electronic or standard cigarette. The study, published in the journal of Environmental and Molecular Mutagenesis, revealed that only traces of the normal cigarette collected in the cells  promoted tumor development. The e-cigarette vapor caused no cancer-related toxicity at any nicotine dose.

Following these findings, the researchers plan to use similar methods to their laboratory cell technique, known as a Bhas 42 assay, to continue to compare conventional and electronic cigarettes. Study author Dr Damien Breheny stated:
This is the first time this particular test, the Bhas 42 assay, has been used to compare tobacco and nicotine products. It is one of a series of tests being developed and refined by British American Tobacco to compare the relative biological effects of e-cigarettes and tobacco-heating products with conventional cigarettes.


Supporting published research data for further reference:

Abstract from Comparative tumor promotion assessment of e-cigarette and cigarettes using the in vitro Bhas 42 cell transformation assay


In vitro cell transformation assays (CTA) are used to assess the carcinogenic potential of chemicals and complex mixtures and can detect non genotoxic as well as genotoxic carcinogens. The Bhas 42 CTA has been developed with both initiation and promotion protocols to distinguish between these two carcinogen classes. Cigarette smoke is known to be carcinogenic and is positive in in vitro genotoxicity assays. Cigarette smoke also contains nongenotoxic carcinogens and is a tumour promoter and cocarcinogen in vivo. We have combined a suite of in vitro assays to compare the relative biological effects of new categories of tobacco and nicotine products with traditional cigarettes. The Bhas promotion assay has been included in this test battery to provide an in vitro surrogate for detecting tumor promoters. The activity of an electronic cigarette (e-cigarette; Vype ePen) was compared to that of a reference cigarette (3R4F) in the promotion assay, using total particulate matter (TPM)/aerosol collected matter (ACM) and aqueous extracts (AqE) of product aerosol emissions. 3R4F TPM was positive in this assay at concentrations ≥6 µg/mL, while e-cigarette ACM did not have any promoter activity. AqE was found to be a less suitable test matrix in this assay due to high cytotoxicity. This is the first study to use the Bhas assay to compare tobacco and nicotine products and demonstrates the potential for its future application as part of a product assessment framework. These data add to growing evidence suggesting that e-cigarettes may provide a safer alternative to traditional cigarettes. Environ. Mol. Mutagen. 58:190–198, 2017. © 2017 Wiley Periodicals, Inc. DOI: 10.1002/em.22091 PMID: 28444993 

0 comments:

Copyright © 2013 Northwest Vaper